Android app Apple app link

CervoMed Shares Rise 15% on FDA's Orphan Drug Designation for Neflamapimod

By MarketWatch   |   1 year ago
CervoMed Shares Rise 15% on FDA's Orphan Drug Designation for Neflamapimod

CervoMed's stock surged 15% following FDA's orphan drug designation for neflamapimod, a frontotemporal dementia treatment. The company plans a proof-of-principle study and Phase 3 trial in mid-2025 for the rare disease affecting thousands worldwide.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.